MA
Therapeutic Areas
Altesa BioSciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Vapendavir | Treatment of rhinovirus infection to prevent acute exacerbations in Chronic Obstructive Pulmonary Disease (COPD) | Phase 2b |
Leadership Team at Altesa BioSciences
BP
Brett P. Giroir, MD
Chief Executive Officer
JM
John M. Clerici, JD
President and Chief Operating Officer
KK
Kate Knobil, MD
Chief Medical Officer
AD
Andy Drechsler
Chief Financial Officer
KF
Karen Fusaro
Senior Vice President, Clinical Development
KL
Katie Laessig, MD
Vice President, Regulatory Affairs
KS
Katherine Squires, PhD
Vice President, Preclinical and Translational Science
AP
Alan Parr, PharmD, PhD
Vice President (Acting), Manufacturing
LK
Laura K. Smart, BA, MA
Vice President, Corporate Affairs
EB
Erica Bitten, MHA, SPHR
Vice President (Acting), Human Resources